|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
SNS-314
Description of SNS-314: SNS-314 is a synthetic
small molecule Aurora kinase (AK) inhibitor with potential
antineoplastic activity. Aurora kinase inhibitor SNS-314 selectively
binds to and inhibits AKs A and B, which may result in the
inhibition of cellular division and proliferation in tumor cells
that overexpress AKs. AKs are serine-threonine kinases that play
essential roles in mitotic checkpoint control during mitosis. Check
for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus).
Current developer: Sunesis
Pharmaceuticals, Inc.
|
MedKoo Code#:
202651
|
|
Name:
SNS-314
|
|
CAS#:
1057249-41-8
Synonym:
SNS-314;
IUPAC/Chemical name:
N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea
|
|
Chemical structure: |
Theoretical analysis
: |
|
|
Chemical Formula: C18H15ClN6OS2 Exact Mass:
430.04373
Molecular Weight: 430.93
Elemental Analysis: C, 50.17; H, 3.51; Cl,
8.23; N, 19.50; O, 3.71; S, 14.88
|
|
Availability and price:
SNS-314 is available through custom
synthesis
To inquire the quotation and lead time of custom synthesis for this agent,
please send email to
sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control data:
Product will be shipped with supporting
analytical data.
|
|
Information about this agent
|
SNS-314 is a potent and sele ctive inhibitor of Aurora kinases A, B, and C. Proliferating cells treated with SNS-314 bypass the
mitotic spindle checkpoint and fail to undergo cytokinesis, leading to
multiple rounds of endoreduplication and eventually cell death.
NS-314 is currently in a dose escalation phase 1
clinical trial for the treatment of patients with advanced solid tumors.
Both the in vitro synergies observed between SNS-314 and agents that
target the mitotic spindle and the potentiation seen with docetaxel in
vivo are consistent with a mechanism of action in which Aurora
inhibition bypasses the mitotic spindle assembly checkpoint and prevents
cytokinesis, augmenting subsequent spindle toxin-mediated mitotic
catastrophe and cell death. For detail see:
http://www.ncbi.nlm.nih.gov/pubmed/19372566.
1: Arbitrario JP, Belmont BJ, Evanchik MJ,
Flanagan WM, Fucini RV, Hansen SK, Harris SO, Hashash A, Hoch U, Hogan
JN, Howlett AR, Jacobs JW, Lam JW, Ritchie SC, Romanowski MJ, Silverman
JA, Stockett DE, Teague JN, Zimmerman KM, Taverna P. SNS-314, a
pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing
flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
Epub 2009 Aug 1. PubMed PMID: 19649632.
2: Zhong M, Bui M, Shen W, Baskaran S, Allen DA, Elling RA, Flanagan WM,
Fung AD, Hanan EJ, Harris SO, Heumann SA, Hoch U, Ivy SN, Jacobs JW, Lam
S, Lee H, McDowell RS, Oslob JD, Purkey HE, Romanowski MJ, Silverman JA,
Tangonan BT, Taverna P, Yang W, Yoburn JC, Yu CH, Zimmerman KM, O'Brien
T, Lew W. 2-Aminobenzimidazoles as potent Aurora kinase inhibitors.
Bioorg Med Chem Lett. 2009 Sep 1;19(17):5158-61. Epub 2009 Jul 9. PubMed
PMID: 19646866.
3: VanderPorten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM,
Fucini RV. The Aurora kinase inhibitor SNS-314 shows broad therapeutic
potential with chemotherapeutics and synergy with microtubule-targeted
agents in a colon carcinoma model. Mol Cancer Ther. 2009 Apr;8(4):930-9.
PubMed PMID: 19372566.
4: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp
Clin Pharmacol. 2009 Jan-Feb;31(1):47-57. PubMed PMID: 19357798.
5: Oslob JD, Heumann SA, Yu CH, Allen DA, Baskaran S, Bui M, Delarosa E,
Fung AD, Hashash A, Hau J, Ivy S, Jacobs JW, Lew W, Maung J, McDowell
RS, Ritchie S, Romanowski MJ, Silverman JA, Yang W, Zhong M, Fuchs-Knotts
T. Water-soluble prodrugs of an Aurora kinase inhibitor. Bioorg Med Chem
Lett. 2009 Mar 1;19(5):1409-12. Epub 2009 Jan 19. PubMed PMID: 19186057.
6: Oslob JD, Romanowski MJ, Allen DA, Baskaran S, Bui M, Elling RA,
Flanagan WM, Fung AD, Hanan EJ, Harris S, Heumann SA, Hoch U, Jacobs JW,
Lam J, Lawrence CE, McDowell RS, Nannini MA, Shen W, Silverman JA, Sopko
MM, Tangonan BT, Teague J, Yoburn JC, Yu CH, Zhong M, Zimmerman KM,
O'Brien T, Lew W. Discovery of a potent and selective aurora kinase
inhibitor. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4880-4. Epub 2008 Jul
24. PubMed PMID: 18678489.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
